Brigger Irène, Dubernet Catherine, Couvreur Patrick
University of Paris-Sud XI, UMR CNRS 8612, Faculty of Pharmacy, 5 rue J.B. Clément, 92296 Châtenay-Malabry, France.
Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51. doi: 10.1016/s0169-409x(02)00044-3.
Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for 'active' targeting of cancerous cells, are also discussed here. The last part of this review focus on the application of nanoparticles in imaging for cancer diagnosis.
大量研究表明，抗癌药物的组织和细胞分布情况可通过将其包裹于亚微米胶体系统（纳米颗粒）中加以控制。这种方法背后的基本原理是提高抗肿瘤疗效，同时降低全身副作用。本综述提供了关于传统或长循环纳米颗粒肿瘤靶向的最新情况。讨论了这些系统在血管内或肿瘤内给药后的体内命运，以及肿瘤消退所涉及的机制。纳米颗粒对于将寡核苷酸选择性递送至肿瘤细胞也有益处。此外，某些类型的纳米颗粒显示出一些有趣的逆转多药耐药性的能力，而多药耐药性是化疗中的一个主要问题。本文还讨论了旨在用分子配体修饰纳米颗粒以“主动”靶向癌细胞的首批实验。本综述的最后一部分重点关注纳米颗粒在癌症诊断成像中的应用。
